Gutiérrez-Aguirre CH, González-Leal XJ, Herrera-Pérez FC, Zacarías-Reyes BC, Herrera-Rojas MÁ, Gómez-Almaguer D

Language: Spanish
References: 19
Page: 87-94
PDF size: 400.68 Kb.

ABSTRACT

Background: The “7+3” induction chemotherapy regimen used in patients with acute myelogenous leukemia is effective in 80% of the cases, but with 2 year overall survival of only 20%. The options of postremission therapy to prevent relapse are consolidation with high dose of citarabine and autologous (auto-HSCT) or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The effectiveness of auto-HSCT is controversial, but it can be a good option for those patients without a match related donor.
Objective: To analyze the effectiveness of the auto-HSCT in patients with acute myeloid leukemia (AML) without a match related donor.
Material and method: A retrospective study were performed with the clinical records of patients that were treated with an auto-HSCT at the Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, México, in the last 10 years. Only patients with AML were included in the study.
Results: Seven patients were included, 5 males and 2 females, with a median of age of 41 years (range: 10-59). In all patients the postremission treatment with auto-HSCT was chosen because they did not have a match related donor. The median of CD34+ cells infused was 2.59 x 10⁶/kg; engraftment was confirmed in all patients, with a median recovery of granulocyte counts on day +14, and platelet count on day +13. The median follow up was 294 days (range: 27-1,300). Relapse was observed in 2 patients (29%) and the overall survival was 58%.
Conclusions: The auto-HSCT is a useful therapeutic option in high-risk patients with AML without a match donor for allo-HSCT

REFERENCES

1. Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:98-117.

2. Tallman MS. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.

3. Casasnovas RO, Slimane FK, Garand R, Faure GC, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003;17:515-527.

4. Jaime-Pérez JC, Brito-Ramírez AS, Pinzón-Uresti M, Gutiérrez- Aguirre H, et al. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in Northeast Mexico: An eight-year experience at a University Hospital Acta Haematol 2014:144-151.

5. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-1692.

6. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62:10-29.

7. Sant M, Allemani C, Tereanu C, De Angelis R, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-3734.

8. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.

9. Gómez-Almaguer D, Flores-Jiménez JA, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH. Utilidad del trasplante de células hematopoyéticas en la leucemia mieloide aguda. Rev Hematol Mex 2012;13:74-79.

10. Breems DA, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005;130:825-833.

11. Lowenberg B, Verdonck LJ, Dekker AW, Willemze R, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990;8:287-294.

12. Eto T, Takase K, Miyamoto T, Ohno Y, et al. Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. Int J Hematol 2013;98:186- 196.

13. Nagler A, Labopin M, Gorin NC, Ferrara F, et al. Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014;99:1380-1386.

14. Keating A, Da Silva G, Perez WS, Gupta V, et al. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica 2013;98:185-192.

15. Keating S, de Witte T, Suciu S, Willemze R, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Br J Haematol 1998;102:1344-1353.

16. Burnett A, Goldstone A, Stevens R, Hann I, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400.

17. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2011;87:89-99.

18. Lazarus HM, Perez WS, Klein JP, Kollman C, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006;132:755-769.

19. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118:6037-6042.